Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer CEO Albert Bourla says he used extreme team-motivating tactics to meet seemingly impossible deadlines during the COVID-19 pandemic. Specifically, his team was tasked with creating a vaccine to ...

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent cliffs. Read more here.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read the full analysis before buying.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...